Vifor Pharma AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Vifor Pharma AG with three other
pharmaceutical manufacturers in Europe:
Jazz Pharmaceuticals Plc
sales of 1.60 billion Euro [US$1.73 billion]
of which 74%
Krka DD Novo Mesto
(1.33 billion Euro [US$1.44 billion]
of which 60%
was European Union), and
based in Italy
(1.35 billion Euro [US$1.46 billion]
of which 84%
was Specialty & Primary care).
During the year ended December of 2018, sales at
Vifor Pharma AG were 1.58 billion Swiss Francs (US$1.61 billion).
increase of 18.1%
versus 2017, when the company's sales were 1.34 billion Swiss Francs.
Despite this increase, sales are still
below the level achieved in 2016, when Vifor Pharma AG
reported sales of 4.12 billion Swiss Francs.